Peptide-Drug Conjugates with Different Linkers for Cancer Therapy.
Mona Alas1, Azam Saghaeidehkordi1, Kamaljit Kaur1
1Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California 92618-1908, United States.
Journal of Medicinal Chemistry
|December 31, 2020
Summary
Peptide-drug conjugates (PDCs) offer a promising targeted cancer therapy approach. Linker chemistry is crucial for PDC efficacy and drug release at the tumor site, improving treatment outcomes.
Area of Science:
- Oncology
- Medicinal Chemistry
- Drug Delivery
Background:
- Drug conjugates link cytotoxic agents to targeting ligands for precise delivery.
- Antibody-drug conjugates (ADCs) are established in cancer therapy.
- Peptide-drug conjugates (PDCs) are emerging as a potent targeted cancer treatment modality.
Purpose of the Study:
- To review key linker chemistries used in peptide-drug conjugate (PDC) design.
- To discuss representative PDCs and their linker strategies.
- To analyze the impact of linker chemistry on PDC efficacy in preclinical studies.
Main Methods:
- Literature review of PDC linker chemistries.
- Analysis of published cell and animal study data for various PDCs.
- Categorization of PDCs based on linker type and therapeutic outcome.
Main Results:
- Different linker chemistries significantly influence PDC circulation time and drug release kinetics.
- Specific linker designs correlate with enhanced efficacy and reduced toxicity in preclinical models.
- The choice of linker is critical for optimizing the therapeutic index of PDCs.
Conclusions:
- Linker chemistry is a critical determinant of peptide-drug conjugate (PDC) performance.
- Optimized linker strategies are essential for advancing PDCs as effective cancer therapeutics.
- Further research into novel linker technologies will drive the clinical success of PDCs.
More Related Videos
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.0K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.9K
Related Concept Videos
00:49Ligand Binding and Linkage
5.2K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.2K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
01:14Phase II Conjugation Reactions: Overview
558
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
558
02:43Peptide Bonds
80.4K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
80.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.5K